Protara Therapeutics (TARA) said late Thursday it launched a public offering of $75 million of common shares and pre-funded warrants.
The company plans to grant underwriters a 30-day overallotment option to purchase additional shares, according to a statement.
Net proceeds will be used to advance clinical programs, including the development of the TARA-002 immunotherapy for certain types of cancers, as well as for general corporate purposes, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments